Evidence map›Paper›PMID 33574666›Full record

ArticleInternational journal of nanomedicine2021

Combined Photothermal and Ionizing Radiation Sensitization of Triple-Negative Breast Cancer Using Triangular Silver Nanoparticles.

James Sears, Jessica Swanner, Cale D Fahrenholtz, Christina Snyder, Monica Rohde, Nicole Levi-Polyachenko, Ravi Singh

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

James SearsDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Jessica SwannerDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Cale D FahrenholtzDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-5998-4003
Christina SnyderDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Monica RohdeDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Nicole Levi-PolyachenkoDepartment of Plastic Surgery and Reconstructive Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Ravi SinghDepartment of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0003-0750-1804
Wake Forest University · USAtrium Health Wake Forest Baptist · USHigh Point University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Training Program in Cancer BiologyT32CA079448 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRIDEL, STEVEN J. · 2000 to 2014
$6.5M
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
Redox Biology and Medicine Training ProgramT32GM127261 · NIGMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FURDUI, CRISTINA MARIA, POOLE, LESLIE B · 2018 to 2022
$975k
NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA207222NCI NIH HHS T32 CA079448NIGMS NIH HHS T32 GM127261
6 · The paper itself

Abstract

backgroundIonizing radiation (IR) is commonly used in triple-negative breast cancer (TNBC) treatment regimens. However, off-target toxicity affecting normal tissue and grueling treatment regimens remain major limitations. Hyperthermia is one of the greatest IR sensitizers, but only if heat is administered simultaneously or immediately prior to ionizing radiation. Difficulty in co-localizing ionizing radiation (IR) in rapid succession with hyperthermia, and confining treatment to the tumor have hindered widespread clinical adoption of combined thermoradiation treatment. Metal nanoparticle-based approaches to IR sensitization and photothermal heat generation may aid in overcoming these issues and improve treatment specificity.

methodsWe assessed the potential to selectively treat MDA-MB-231 TNBC cells without affecting non-malignant MCF-10A breast cells using a multimodal approach based upon combined photothermal therapy, IR sensitization, and specific cytotoxicity using triangular silver nanoparticles (TAgNPs) with peak absorbance in the near-infrared light (NIR) spectrum.

resultsWe found that TAgNP-mediated photothermal therapy and radiosensitization offer a high degree of specificity for treatment of TNBC without affecting non-malignant mammary epithelial cells. DISCUSSION: If given at a high enough dose, IR, heat, or TAgNPs alone could be sufficient for tumor treatment. However, when the dose of one or all of these modalities increases, off-target effects also increase. The challenge lies in identifying the minimal doses of each individual treatment such that when combined they provide maximum selectivity for treatment of TNBC cells with minimum off-target effects on non-malignant breast cells. Our results provide proof of concept that this combination is highly selective for TNBC cells while sparing non-malignant mammary epithelial cells. This treatment would be particularly important for patients undergoing breast conservation therapy and for treatment of invasive tumor margins near the periphery where each individual treatment might be at a sub-therapeutic level.

Indexed as

Photothermal TherapyRadiation, IonizingAnimalsApoptosisCarcinogenesisCell Line, TumorCell SurvivalCombined Modality TherapyFemaleHumansInfrared RaysMetal NanoparticlesRadiation-Sensitizing AgentsSilverTriple Negative Breast NeoplasmsRadiation-Sensitizing AgentsSilvercancerhyperthermialasernanoparticleradiation sensitizer

Identifiers

PMID33574666
PMCPMC7872896
OpenAlexW3126311168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.